找到10记录 | 不满意,请使用左下搜索矩阵
排序: 相关性 发表日期 影响因子

INTRODUCTION: Elderly patients make up a significant proportion of patients with metastatic breas...

期刊:Expert Opin Pharmacother  影响因子:3.038  发表日期: 20180401  PMID: 29601247 


BACKGROUND: The recurrence score based on the 21-gene breast cancer assay predicts chemotherapy b...

关键词:   
期刊:N Engl J Med  影响因子:70.67  发表日期: 20180712  PMID: 29860917 


BACKGROUND: The 21-gene Recurrence Score (RS) assay is only reimbursed in Ontario for node-negati...

期刊:Oncologist  影响因子:5.252  发表日期: 20180701  PMID: 29371476 


BACKGROUND: Current National Comprehensive Cancer Network and American Society of Clinical Oncolo...

期刊:Clin Breast Cancer  影响因子:2.762  发表日期: 20190711  PMID: 31447286 


PURPOSE: Adherence to adjuvant endocrine therapy among post-menopausal breast cancer patients is ...

关键词: Adherence    Breast cancer    Endocrine therapy   
期刊:Breast Cancer Res Treat  影响因子:3.471  发表日期: 20191001  PMID: 31571072 


Aromatase inhibitors (AIs) play an important role in the adjuvant treatment of hormone receptor-p...

关键词:   
期刊:Oncology (Williston Park, NY)  影响因子:0.0  发表日期: 20181115  PMID: 30474104 


In identifying research priorities it is important to take the needs and prospective of patients ...

期刊:Breast  影响因子:3.494  发表日期: 20191101  PMID: 31839153 


BACKGROUND: Fulvestrant, a selective estrogen receptor degrader, is approved for first- and secon...

背景:富勒维斯特是一种选择性雌激素受体降解剂,已被批准用于绝经后激素受体阳性晚期乳腺癌(ABC)妇女的一线和二线治疗。 方法:对绝经后激素受体阳性的ABC中的氟维司群500 mg进行评估的随机对...

期刊:Breast Cancer  影响因子:0.0  发表日期: 20190511  PMID: 31079343 


    相关搜索: